VivoSim Labs (VIVS) Retained Earnings (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Retained Earnings of -$356.0 million for Q1 2026, down 4.05% year-over-year from -$371.0 million in Q1 2025, and down 1.65% quarter-over-quarter from -$350.2 million in Q4 2025.
VivoSim Labs (VIVS) Retained Earnings (2011 - 2026) Analysis & Trends
VivoSim Labs' Retained Earnings history runs 16 years deep, the most recent figure standing at -$356.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 4.05% year-over-year to -$356.0 million; the TTM figure through Mar 2026 stood at -$356.0 million (down 4.05% YoY), while the FY2026 annual figure was -$356.0 million, down 4.05% from the prior year.
- Retained Earnings for Q1 2026 stood at -$356.0 million, down from -$350.2 million in the prior quarter.
- The five-year high for Retained Earnings was $3000.0 in Q4 2022, with the low at -$356.0 million in Q1 2026.
- The 5-year median for Retained Earnings is -$338.1 million (2023), against an average of -$274.8 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 100.0% in 2022, then plunged 34750100.0% in 2025.
- VivoSim Labs' Retained Earnings stood at $3000.0 in 2022, then plunged by 11220900.0% to -$336.6 million in 2023, then retreated by 3.68% to -$349.0 million in 2024, then declined by 0.35% to -$350.2 million in 2025, then slipped by 1.65% to -$356.0 million in 2026.
- Business Quant data shows VIVS's Retained Earnings at -$356.0 million in Q1 2026, -$350.2 million in Q4 2025, and -$347.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -357.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -357.34 Mn |
| Mar 31, 2026 | -356.00 Mn |
| Dec 31, 2025 | -350.24 Mn |
| Sep 30, 2025 | -347.50 Mn |
| Jun 30, 2025 | -345.00 Mn |
| Mar 31, 2025 | -342.16 Mn |
| Dec 31, 2024 | -349.00 Mn |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | -343.00 Mn |
| Mar 31, 2024 | -339.67 Mn |
| Dec 31, 2023 | -336.62 Mn |
| Sep 30, 2023 | -333.00 Mn |
| Jun 30, 2023 | -329.00 Mn |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | -314.30 Mn |
| Jun 30, 2022 | -310.95 Mn |
| Dec 31, 2021 | -305.83 Mn |
| Sep 30, 2021 | -302.33 Mn |
| Jun 30, 2021 | -298.82 Mn |